Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.
Delouvrié B, Al-Kadhimi K, Arnould JC, Barry ST, Cross DA, Didelot M, Gavine PR, Germain H, Harris CS, Hughes AM, Jude DA, Kendrew J, Lambert-van der Brempt C, Lohmann JJ, Ménard M, Mortlock AA, Pass M, Rooney C, Vautier M, Vincent JL, Warin N. Delouvrié B, et al. Among authors: vautier m. Bioorg Med Chem Lett. 2012 Jun 15;22(12):4117-21. doi: 10.1016/j.bmcl.2012.04.061. Epub 2012 Apr 21. Bioorg Med Chem Lett. 2012. PMID: 22572578
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1.
Delouvrié B, Al-Kadhimi K, Arnould JC, Barry ST, Cross DA, Didelot M, Gavine PR, Germain H, Harris CS, Hughes AM, Jude DA, Kendrew J, Lambert-van der Brempt C, Lohmann JJ, Ménard M, Mortlock AA, Pass M, Rooney C, Vautier M, Vincent JL, Warin N. Delouvrié B, et al. Among authors: vautier m. Bioorg Med Chem Lett. 2012 Jun 15;22(12):4111-6. doi: 10.1016/j.bmcl.2012.04.063. Epub 2012 Apr 21. Bioorg Med Chem Lett. 2012. PMID: 22575869
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Barlaam B, Acton DG, Ballard P, Bradbury RH, Cross D, Ducray R, Germain H, Hudson K, Klinowska T, Magnien F, Ogilvie DJ, Olivier A, Ross HS, Smith R, Trigwell CB, Vautier M, Wright L. Barlaam B, et al. Among authors: vautier m. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1799-803. doi: 10.1016/j.bmcl.2008.02.035. Epub 2008 Feb 16. Bioorg Med Chem Lett. 2008. PMID: 18313293
Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.
Barlaam B, Cosulich S, Degorce S, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann JJ, Maudet M, Morgentin R, Pasquet MJ, Péru A, Plé P, Saleh T, Vautier M, Walker M, Ward L, Warin N. Barlaam B, et al. Among authors: vautier m. J Med Chem. 2015 Jan 22;58(2):943-62. doi: 10.1021/jm501629p. Epub 2015 Jan 7. J Med Chem. 2015. PMID: 25514658
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
Barlaam B, Cosulich S, Delouvrié B, Ellston R, Fitzek M, Germain H, Green S, Hancox U, Harris CS, Hudson K, Lambert-van der Brempt C, Lebraud H, Magnien F, Lamorlette M, Le Griffon A, Morgentin R, Ouvry G, Page K, Pasquet G, Polanska U, Ruston L, Saleh T, Vautier M, Ward L. Barlaam B, et al. Among authors: vautier m. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5155-62. doi: 10.1016/j.bmcl.2015.10.002. Epub 2015 Oct 9. Bioorg Med Chem Lett. 2015. PMID: 26475521
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Barlaam B, Ballard P, Bradbury RH, Ducray R, Germain H, Hickinson DM, Hudson K, Kettle JG, Klinowska T, Magnien F, Ogilvie DJ, Olivier A, Pearson SE, Scott JS, Suleman A, Trigwell CB, Vautier M, Whittaker RD, Wood R. Barlaam B, et al. Among authors: vautier m. Bioorg Med Chem Lett. 2008 Jan 15;18(2):674-8. doi: 10.1016/j.bmcl.2007.11.052. Epub 2007 Nov 21. Bioorg Med Chem Lett. 2008. PMID: 18061446
Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.
Saadoun D, Maalouf G, Vieira M, Trad S, Lazaro E, Sacre K, Plessier A, Sené T, Koné-Paut I, Noel N, Mekinian A, Lambert M, Ribeiro E, Mirault T, Mele N, Dellal A, Fain O, Melki I, Chiche L, Gaudric J, Redheuil A, Maillart E, Ghembaza A, Desbois AC, Mirouse A, Domont F, Leroux G, Ferfar Y, Rigolet A, Viallard JF, Vautier M, Resche-Rigon M, Cacoub P. Saadoun D, et al. Among authors: vautier m. NEJM Evid. 2024 Nov;3(11):EVIDoa2300354. doi: 10.1056/EVIDoa2300354. Epub 2024 Oct 22. NEJM Evid. 2024. PMID: 39437137 Clinical Trial.
Guselkumab in Behçet's disease.
Ghayad EE, Maalouf G, Mekinian A, Emmi G, Vieira M, Mirouse A, Desbois AC, Le Joncour A, Domont F, Leroux G, Bugaut H, Vautier M, Cacoub P, Barete S, Saadoun D. Ghayad EE, et al. Among authors: vautier m. Ann Rheum Dis. 2024 Nov 14;83(12):1794-1796. doi: 10.1136/ard-2024-225913. Ann Rheum Dis. 2024. PMID: 39317416 No abstract available.
Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis.
Leclercq M, Sève P, Biard L, Vautier M, Maalouf G, Leroux G, Domont F, Toutée A, Fardeau C, Sales de Gauzy T, Touhami S, Kodjikian L, Cacoub P, Bodaghi B, Saadoun D, Desbois AC. Leclercq M, et al. Among authors: vautier m. Br J Ophthalmol. 2024 Jul 16:bjo-2024-325163. doi: 10.1136/bjo-2024-325163. Online ahead of print. Br J Ophthalmol. 2024. PMID: 39013629
58 results